©TheCanadian Journal ofUrology™: International Supplement, April 2014
97
Dreicer
9. RyanCJ, SmithMR, deBono JSet al.Abiraterone inmetastatic
prostate cancerwithout previous chemotherapy.
NEngl JMed
2013;368(2):138-148.
10.Garcia J, Dreicer R. Immunotherapy in castration-resistant
prostate cancer: integrating sipuleucel-T into our current
treatmentparadigm.
Oncology(WillistonPark)
2011;25(3):242-249.
11. SchellhammerPF,ChodakG,WhitmoreJB,SimsR,FrohlichMW,
KantoffPW.Lowerbaselineprostate-specificantigenisassociated
with a greater overall survival benefit from sipuleucel-T in
the immunotherapy for prostate adenocarcinoma treatment
(IMPACT) trial.
Urology
2013;81(6):1297-1302.
12.SmallE,LanceR,RedfernCetal.Arandomizedphase II trialof
sipuleucel-Twith concurrent or sequential abirateroneacetate
plusprednisone inmetastaticcastrate-resistantprostatecancer.
J ClinOncol
2013;31:abstr 5047.
13.NoonanKL,NorthS,BittingRL,ArmstrongAJ,EllardSL,ChiKN.
Clinical activity of abiraterone acetate in patients with
metastaticcastration-resistantprostatecancerprogressingafter
enzalutamide.
AnnOncol
2013;24(7):1802-1807.
14.SchraderA, BoegemannM,OhlmannCet al. Enzalutamide in
castration-resistant prostate cancer patients progressing after
docetaxel and abiraterone.
EurUrol
2014;65(1):30-36.
15.Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of
abiraterone acetate against metastatic castration-resistant
prostate cancer progressing after docetaxel and enzalutamide
(MDV3100).
AnnOncol
2013;24(7):1807-1812.
16.Tannock I, deWit R, BerryW et al. Docetaxel plus prednisone
ormitoxantroneplusprednisone foradvancedprostatecancer.
NEngl JMed
2004;351(15):1502-1512.
17.Agency for Health Care Policy and Research. Relative
effectiveness and cost-effectiveness of methods of androgen
suppression in the treatment of advanced prostatic cancer.
EvidenceReport/TechnologyAssessment, no. 4:73.
18.Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C.
A population-based study of prostate cancer chemotherapy.
ClinOncol (RColl Radiol)
2011;23(10):706-708.
19.LeeRJ,SaylorPJ,DrorMichaelsonMetal.Adose-rangingstudy
ofcabozantinib inmenwithcastration-resistantprostatecancer
andbonemetastases.
ClinCancerRes
2013;19(11):3088-3094.
20.Slovin SF, HiganoCS, HamidO et al. Ipilimumab alone or in
combinationwithradiotherapy inmetastaticcastration-resistant
prostate cancer: results from anopen-label,multicenter phase
I/II study.
AnnOncol
2013;24(7):1813-1821.
21.SaadF,HotteS,NorthSetal.RandomizedphaseIItrialofcustirsen
(OGX-011) in combination with docetaxel or mitoxantrone as
second-line therapy inpatientswithmetastaticcastrate-resistant
prostatecancerprogressingafterfirst-linedocetaxel:CUOG trial
P-06c.
ClinCancerRes
2011;17(17):5765-5773.
